VA
AUTL

Vident Advisory’s Autolus Therapeutics AUTL Stock Holding History

Vident Advisory’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-155,504
Closed -$241K – 1607
2025
Q1 		$241K Buy
+155,504
New +$316K ﹤0.01% 1355

Other funds holding AUTL

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Vident Advisory's AUTL Position: Q2 2025 in Review

Vident Advisory sold out of Autolus Therapeutics (AUTL) in Q2 2025, closing a stake of 155,504 shares — an estimated $241K sold.

Vident Advisory first reported a position in AUTL in Q1 2025 and held it in 1 quarter. The position peaked at $241K in Q1 2025. 94 funds tracked by Wall St. Rank hold AUTL as of Q2 2025.

  • Vident Advisory reported no remaining Autolus Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Vident Advisory sold 155,504 Autolus Therapeutics shares in Q2 2025, an estimated $241K.
  • Vident Advisory first reported a position in Autolus Therapeutics in Q1 2025 and held it in 1 quarter.
  • Vident Advisory's Autolus Therapeutics position peaked at $241K in Q1 2025.
  • 94 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2025.

Based on Vident Advisory's 13F filing for Q2 2025, filed 14 Aug 2025.